Which statement about the administration of medroxyprogesterone acetate (Depo-Provera) is NOT true?

Which statement about the administration of medroxyprogesterone acetate (Depo-Provera) is NOT true?

• A. Menses may not return for 3 to 12 months after the last injection
• B. Depo-Provera must be discontinued 6 months before attempting pregnancy
• C. Patients should be advised to take calcium and vitamin D while using Depo-Provera
• D. Few drug-drug interactions are associated with intramuscular Depo-Provera

Answer: (D)

The administration of medroxyprogesterone acetate, commonly known as Depo-Provera, is associated with various clinical guidelines and patient considerations. The statement that few drug-drug interactions are associated with intramuscular Depo-Provera is not accurate. In fact, there are some notable interactions that healthcare providers need to be aware of, particularly with medications that can affect the metabolism of hormones, such as certain anticonvulsants and rifampin. These interactions could potentially reduce the effectiveness of Depo-Provera in preventing pregnancy. The other statements regarding Depo-Provera are true and reflect the considerations that patients should understand when using this contraceptive method. For example, it is indeed possible for menses to be absent for an extended period after discontinuation, and providers typically advise that women should not attempt pregnancy for a period following the last injection to ensure the hormone clears from their system adequately. Moreover, calcium and vitamin D supplementation is recommended due to the potential negative impact on bone density associated with long-term use of Depo-Provera. Each of these points addresses an important aspect of patient education and management when prescribing this medication.

The administration of medroxyprogesterone acetate, commonly known as Depo-Provera, is associated with various clinical guidelines and patient considerations. The statement that few drug-drug interactions are associated with intramuscular Depo-Provera is not accurate. In fact, there are some notable interactions that healthcare providers need to be aware of, particularly with medications that can affect the metabolism of hormones, such as certain anticonvulsants and rifampin. These interactions could potentially reduce the effectiveness of Depo-Provera in preventing pregnancy.

The other statements regarding Depo-Provera are true and reflect the considerations that patients should understand when using this contraceptive method. For example, it is indeed possible for menses to be absent for an extended period after discontinuation, and providers typically advise that women should not attempt pregnancy for a period following the last injection to ensure the hormone clears from their system adequately. Moreover, calcium and vitamin D supplementation is recommended due to the potential negative impact on bone density associated with long-term use of Depo-Provera. Each of these points addresses an important aspect of patient education and management when prescribing this medication.